Rothschild & Co Redburn analyst Natalya Davies initiated coverage of Waters (WAT) with a Buy rating and $390 price target The firm sees the life science equipment market returning to “normalized growth” of 4%-6% over the medium term, bolstered by persistent innovation in analytical instrumentation. The analyst sees upside in Waters due to the company’s acquisition of Becton Dickinson’s Biosciences and Diagnostics business. Rothschild views the deal as value-accretive.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAT: